Literature DB >> 1199992

Pancreatic excretion of 5,5-dimethyl-2,4-oxazolidinedione in patients with chronic pancreatitis.

A Noda, T Hayakawa, I Aoki, Y Horiguchi, Y Toda.   

Abstract

Abnormal pancreatic excretion of 5,5-dimethyl-2,4-oxazolidinedione (DMO) was demonstrated in 44 patients with chronic pancreatitis (14 with calcification and 30 without calcification). Pancreatic excretion of DMO in patients with chronic pancreatitis, as well as in normal subjects, depended on plasma DMO concentration and secretory volume. In the postsecretin 60-min period, almost all patients showed a decrease in total DMO output of duodenal aspirate over the observed range of plasma DMO concentration. More than half the patients without calcification gave a discordant pattern between the DMO output and volume, ie, decreased DMO output with normal volume secretion, while most of patients with calcification had low DMO output with decreased volume flow. The data of the pancreozymin-secretin test suggested that chornic pancreatic inflammation was moderate or minimal in patients without calcification and far advanced in those with calcification. From these results the hypothesis was advanced that DMO diffusion into the pancreatic ducts might be primarily impaired in the relatively early stage of chronic pancreatitis, and as the inflammation progressed to the final stage, DMO outflow from the ducts to the duodenum would be disturbed with evolving diffusion impairment of the compound. Total DMO output, when expressed as the output at a level of 10 mg/100 ml of plasma DMO (standard DMO output), was significantly reduced in chronic pancreatitis during a 60-min period after secretin stimulation. DMO in duodenal content, when expressed in terms of maximal concentration ratio of duodenal juice/plasma for the compound (maximal J/P ratio), was significantly low in chronic pancreatitis during the last 40-min period after secretin stimulation. These two parameters can therefore be used as indices of pancreatic excretion of DMO. The present technique may well become an effective diagnostic tool for early detection of chronic pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1199992     DOI: 10.1007/bf01071189

Source DB:  PubMed          Journal:  Am J Dig Dis        ISSN: 0002-9211


  10 in total

1.  Pancreozymin-secretin test. The combined study of serum enzymes and duodenal contents in the diagnosis of pancreatic disease.

Authors:  D C SUN; H SHAY
Journal:  Gastroenterology       Date:  1960-04       Impact factor: 22.682

2.  A stable starch substrate for the determination of amylase in serum and other body fluids.

Authors:  W T CARAWAY
Journal:  Am J Clin Pathol       Date:  1959-07       Impact factor: 2.493

Review 3.  Chronic calcifying pancreatitis--chronic alcoholic pancreatitis.

Authors:  H Sarles
Journal:  Gastroenterology       Date:  1974-04       Impact factor: 22.682

4.  Secretory patterns in minimal pancreatic inflammatory pathologies.

Authors:  D A Dreiling; O Bordalo
Journal:  Am J Gastroenterol       Date:  1973-07       Impact factor: 10.864

5.  The excretion of 5,5-dimethyl-2,4-oxazolidinedione from the canine pancreas and liver.

Authors:  A Noda; Y Toda; T Hayakawa; S Nakajima
Journal:  Am J Dig Dis       Date:  1973-06

6.  [Determination of the concentration of bicarbonate ion in the duodenal fluid using autotitrator].

Authors:  A Noda; Y Toda; T Hayakawa; S Kikuchi; H Ando
Journal:  Rinsho Byori       Date:  1972-03

7.  Choleretic effects of secretin and histamine in the dog.

Authors:  R S Jones; M I Grossman
Journal:  Am J Physiol       Date:  1969-08

8.  A secretin test with high doses of secretin and correction for incomplete recovery of duodenal juice.

Authors:  H O Lagerlöf; H B Schütz; S Holmer
Journal:  Gastroenterology       Date:  1967-01       Impact factor: 22.682

9.  Pancreatic excretion of 5, 5-dimethyl-2, 4-oxazolidinedione in normal subjects.

Authors:  A Noda; T Hayakawa; S Nakajima; T Suzuki; Y Toda
Journal:  Am J Dig Dis       Date:  1975-11

10.  Quantitative studies of the demethylation of trimethadione (tridione).

Authors:  T C BUTLER
Journal:  J Pharmacol Exp Ther       Date:  1953-05       Impact factor: 4.030

  10 in total
  5 in total

1.  Effect of dimethadione derived from repeated oral administration of trimethadione on pancreatic secretion in dogs.

Authors:  A Noda; I Okumura; E Ibuki; S Hotta; K Nomoto; E Miyamoto; K Takeuchi; T Watanabe
Journal:  Gastroenterol Jpn       Date:  1990-10

2.  Macroautoradiographic and densitometric studies of [14C]dimethadione in rats: accumulation of the compound in the pancreas.

Authors:  A Noda; S Kameya; E Isobe; I Okumura; H Kato; T Watanabe; T Fujii; H Miyazaki
Journal:  Gastroenterol Jpn       Date:  1988-02

3.  The excretion of dimethadione in pure pancreatic juice and bile in postoperative patients.

Authors:  A Noda; T Hayakawa; R Mizuno; H Hamano; T Murase; T Shibata
Journal:  Gastroenterol Jpn       Date:  1984-04

4.  Clinical evaluation of pancreatic excretion test with dimethadione and oral BT-PABA test in chronic pancreatitis.

Authors:  A Noda; T Hayakawa; T Kondo; N Katada; A Kameya
Journal:  Dig Dis Sci       Date:  1983-03       Impact factor: 3.199

5.  Comparative pharmacokinetic study of trimethadione and dimethadione for lysis of pancreatic stones.

Authors:  A Noda; K Yamamoto; Y Nakanishi
Journal:  Gastroenterol Jpn       Date:  1986-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.